Documentos relacionados

1. Real-life experience after 3 months with tezepelumab before marketing approval.
2. Adverse events of anti-IL-5 drugs in patients with eosinophilic asthma: a meta-analysis of randomized controlled trials and real-world evidence-based assessments.
3. Identification of cough-variant asthma phenotypes based on clinical and pathophysiologic data.
4. Benralizumab affects NK cell maturation and proliferation in severe asthmatic patients.
5. What trials do and do not tell us about treatments for severe asthma.
6. Airway autoimmunity, asthma exacerbations, and response to biologics.
7. Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity.
8. Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation.
9. Remission in asthma.
10. Cost-effectiveness and resource use analysis of patients with asthma before and after treatment with mepolizumab in a real-life setting.